FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasiliigtori,	D.C.	20343

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Warden Charles M (Last) (First) (Middle) C/O OCULAR THERAPEUTIX, INC.							2. Issuer Name and Ticker or Trading Symbol OCULAR THERAPEUTIX, INC [OCUL] 3. Date of Earliest Transaction (Month/Day/Year) 06/10/2015									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below)					
	SBY DRIVI	A (01730 Zip)		4. If	Amer	ndment,	Date o	of Origina	al File	d (Month/Da	ay/Ye	ar)		. Indivine)	Form	n filed by O	oup Filing (Check Applicable One Reporting Person More than One Reporting			
1. Title of S	Security (Inst	ative					quired, Disposed of, or Benefic 3.					or 5. Amount of				wnership n: Direct	7. Nature of Indirect				
Date (Mont					ay/Year) if a		any Ionth/Day/Year)		Code (8)		5) Amount		(A) or (D)	Price	_	Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		(D) or Indirect (I) (Instr. 4)		Beneficial Ownership (Instr. 4)	
Common Stock 0				06/10	06/10/2015				S		424,494	4	D	\$22	2	2,520,499			I	See Footnote ⁽¹⁾	
Common Stock 06/					10/2015				S		2,506	,506 D		\$22	2	! 14,885			I	See Footnote ⁽²⁾	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) Fixe of Derivative Security 3. Transaction Execution Date, if any (Month/Day/Year) (Month/Day/Year) 4. Transaction Execution Date, if any (Month/Day/Year) 5. Code Execution Date, if any (Month/Day/Year) 6. Code					6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		nstr. 3	8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)					

Explanation of Responses:

- 1. These securities are directly held by Versant Venture Capital III, L.P. Versant Ventures III, LLC is the general partner of Versant Venture Capital III, L.P. The Reporting Person is a mananging member of Versant Ventures III, LLC and disclaims beneficial ownership of the securities listed above except to the extent of his pecuniary interest, if any, therein.
- 2. These securities are directly held by Versant Side Fund III, L.P. Versant Ventures III, LLC is the general partner of Versant Side Fund III, L.P. The Reporting Person is a mananging member of Versant Ventures III, LLC and disclaims beneficial ownership of the securities listed above except to the extent of his pecuniary interest, if any, therein.

Remarks:

/s/ W. Bradford Smith,

Attorney-in-Fact for Charles

M. Warden

** Signature of Reporting Person Date

06/11/2015

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.